Evidence map›Paper›PMID 41667184›Full record

ArticleBMJ open2026

Characterising cystic fibrosis in African populations: a scoping review protocol on phenotype, diagnosis, genetics and barriers to care.

Leah Ratner, Diana Marangu-Boore, Samia Hamouda, Sandra Kwarteng Owusu, Joy Eze, Areej Dakshi, Seyram Wordui, Ahmed Hamdy, Sheila Agyeiwaa Owusu, Yeshidinber Weldetsadik and 9 more

Abstract read
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Leah RatnerDivision of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA LRatner@bwh.harvard.edu.ORCID http://orcid.org/0000-0001-6326-3543
Diana Marangu-BoorePaediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Samia HamoudaBechir Hamza Children's Hospital, Al Manar University, Tunis, Tunisia.
Sandra Kwarteng OwusuDepartment of Child Health, School of Medical Sciences, KNUST, Kumasi, Ashanti Region, Ghana.
Joy EzeDepartment of Paediatrics, University of Nigeria/University of Nigeria Teaching Hospital Ituku-Ozalla, Lagos, Nigeria.
Areej DakshiRespirtory disease, Abusetta Hospital for Respiratory Hospital, Tripoli, Libya.
Seyram WorduiDepartment of Child Health, Korle Bu Teaching Hospital, Accra, Ghana.
Ahmed HamdyFaculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Sheila Agyeiwaa OwusuUniversity for Development Studies, Tamale, Ghana.
Yeshidinber WeldetsadikPediatric Pulmonary and Critical Care, St Paul's Millennium Medical College, Addis Abbaba, Ethiopia.
Ahmet UluerDivision of Pulmonary Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Houria DaimiFaculty of Sciences, University of Gabès, Gabès, Tunisia.
Nada El MakhzenInstitute for Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland.
Hugues AbrielInstitute for Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland.
Samya NasrPediatrics, Section of Pulmonary Medicine, University of Michigan Michigan Medicine, Ann Arbor, Michigan, USA.
Shahida MoosaDepartment of Molecular Biology and Human Genetics, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa.
Chandra SwansonDivision of Pulmonary Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Alexandria E CroninCountway Library, Harvard Medical School, Boston, Massachusetts, USA.
Marco ZampoliUniversity of Cape Town, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCystic fibrosis (CF) is a life-shortening genetic disorder traditionally mischaracterised as affecting only populations of European descent. This framing has contributed to under-recognition of CF in African populations, despite emerging evidence of both common and region-specific cystic fibrosis transmembrane conductance regulator mutations across the continent. Diagnostic barriers, structural inequities and lack of surveillance further exacerbate disparities in care and visibility. METHODS AND ANALYSIS: This scoping review aims to characterise CF in African populations by synthesising evidence on clinical presentation, diagnostic practices, genotypic diversity, prevalence and structural barriers to care. We will include case reports, cohort studies, registry analyses and other primary data sources involving individuals of African descent with suspected or confirmed CF. Key outcomes include clinical phenotype, age at diagnosis, mutation profile, diagnostic testing access and mortality. Data sources include Ovid Medline, Embase, Ebsco Global Health, CAB Abstracts and Web of Science Core Collection. Multiple-reviewer screening and extraction will be conducted. We will use narrative synthesis, thematic analysis and meta-analysis for prevalence where feasible. ETHICS AND DISSEMINATION: No ethical approval is required as the review uses published data. Results will be shared with clinicians, researchers and CF networks in Africa and globally to inform diagnostic strategies and policy.

Indexed as

African PeopleCystic FibrosisHealth Services AccessibilityAfricaBlack PeopleCystic Fibrosis Transmembrane Conductance RegulatorHumansMutationPhenotypePrevalenceResearch DesignScoping Reviews as TopicCystic Fibrosis Transmembrane Conductance RegulatorCystic fibrosisHealth EquityPulmonary DiseaseSOCIAL MEDICINESystematic ReviewVulnerable Populations

Identifiers

PMID41667184
PMCPMC12911761

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.